​

Belite Bio (BLTE) Stock Forecast, Price Target & Predictions

OverviewOwnershipChartTranscripts

BLTE Stock Forecast

Belite Bio (BLTE) stock forecast, based on 6 Wall Street analysts, predicts a 12-month average price target of $245.83, with a high of $303.00 and a low of $206.00. This represents a 66.86% increase from the last price of $147.33.

$100 $150 $200 $250 $300 $350 High: $303 Avg: $245.83 Low: $206 Last Closed Price: $147.33

BLTE Stock Rating

Belite Bio stock's rating consensus is Buy, based on 6 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 6 0 6 Strong Sell Sell Hold Buy Strong Buy

BLTE Price Target Upside V Benchmarks

TypeNameUpside
StockBelite Bio66.86%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-718
Avg Price Target-$241.71$212.56
Last Closing Price$147.33$147.33$147.33
Upside/Downside-64.06%44.27%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 2627---9
Sep, 2626---8
Aug, 2626---8
Jul, 2626---8
Jun, 2626---8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 09, 2026Graig SuvannavejhMizuho Securities$234.00$192.8521.34%58.83%
Sep 08, 2026H.C. Wainwright$245.00$192.7727.09%66.29%
Sep 04, 2026Canaccord Genuity$303.00$171.0977.10%105.66%
Aug 14, 2026Morgan Stanley$206.00$164.0125.60%39.82%
Aug 14, 2026Steve SeedhouseCantor Fitzgerald$270.00$162.8265.83%83.26%
Aug 14, 2026Graig SuvannavejhMizuho Securities$220.00$166.2832.31%49.32%
Aug 12, 2026Yi ChenH.C. Wainwright$214.00$177.5820.51%45.25%
May 26, 2026Graig SuvannavejhMizuho Securities$215.00$137.3056.59%45.93%
May 22, 2026Truist Financial$217.00$140.3554.61%47.29%
Mar 04, 2026Yi ChenH.C. Wainwright$200.00$171.5116.61%35.75%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 15, 2026H.C. WainwrightBuyBuyhold
Sep 09, 2026JefferiesHoldHoldhold
Sep 03, 2026H.C. WainwrightBuyBuyhold
Aug 14, 2026Morgan StanleyOverweightOverweighthold
Aug 14, 2026BenchmarkBuyBuyhold
Aug 12, 2026Cantor FitzgeraldOverweightOverweighthold
Aug 12, 2026H.C. WainwrightBuyBuyhold
Jul 22, 2026H.C. WainwrightBuyBuyhold
Jun 16, 2026H.C. WainwrightBuyBuyhold
May 22, 2026BenchmarkBuyBuyhold

Financial Forecast

EPS Forecast

$-2 $-1 $0 $1 $2 $3 $4 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.19-----
Avg Forecast$-1.29$-1.17$-1.01$-0.61$0.54$3.44
High Forecast$-1.25$-1.14$0.12$0.12$1.17$3.44
Low Forecast$-1.36$-1.23$-1.58$-1.59$-0.50$3.44
Surprise %-7.75%-----

Revenue Forecast

$0 $50M $100M $150M $200M $250M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast-$16.67M$16.67M$55.95M$106.09M$245.76M
High Forecast-$16.67M$16.67M$55.95M$106.09M$245.76M
Low Forecast-$16.67M$16.67M$55.95M$106.09M$245.76M
Surprise %------

Net Income Forecast

$-50M $-20M $10M $40M $70M $100M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-31.63M-----
Avg Forecast$-34.64M$-31.55M$-31.56M$-20.11M$18.99M$91.39M
High Forecast$-33.22M$-30.39M$3.25M$3.19M$31.04M$91.39M
Low Forecast$-36.06M$-32.71M$-41.91M$-42.28M$-13.34M$91.39M
Surprise %-8.68%-----

BLTE Forecast FAQ

Is Belite Bio stock a buy?

Belite Bio stock has a consensus rating of Buy, based on 6 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Belite Bio is a favorable investment for most analysts.

What is Belite Bio's price target?

Belite Bio's price target, set by 6 Wall Street analysts, averages $245.83 over the next 12 months. The price target range spans from $206 at the low end to $303 at the high end, suggesting a potential 66.86% change from the previous closing price of $147.33.

How does Belite Bio stock forecast compare to its benchmarks?

Belite Bio's stock forecast shows a 66.86% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Belite Bio over the past three months?

  • October 2026: 22.22% Strong Buy, 77.78% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Belite Bio’s EPS forecast?

Belite Bio's average annual EPS forecast for its fiscal year ending in December 2024 is $-1.17, marking a -1.68% decrease from the reported $-1.19 in 2023. Estimates for the following years are $-1.01 in 2025, $-0.61 in 2026, $0.54 in 2027, and $3.44 in 2028.

What is Belite Bio’s revenue forecast?

Belite Bio's average annual revenue forecast for its fiscal year ending in December 2024 is $16.67M, reflecting a 0% decrease from the reported $0 in 2023. The forecast for 2025 is $16.67M, followed by $55.95M for 2026, $106.09M for 2027, and $245.76M for 2028.

What is Belite Bio’s net income forecast?

Belite Bio's net income forecast for the fiscal year ending in December 2024 stands at $-31.554M, representing a -0.25% decrease from the reported $-31.632M in 2023. Projections indicate $-31.558M in 2025, $-20.109M in 2026, $18.99M in 2027, and $91.39M in 2028.